Karim Fizazi 的精彩报告！PEACE-1 随访 7.7 年：在 ADT + docetaxel 基础上加用 abiraterone，将新诊断 mCSPC 患者的中位 OS 从 4.4 年提升至 6.2 年（HR 0.68）。初始强化治疗带来持久获益！@myESMO #ESMO26 @oncoalert
288 浏览 · 9 赞 · 4 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Toni Choueiri, MD · x.com